Core Viewpoint - Haizheng Pharmaceutical reported steady growth in its business performance for the first half of 2025, focusing on business growth and efficiency improvement, achieving operating revenue of 5.25 billion yuan and a net profit attributable to shareholders of 299 million yuan, with a 23.92% year-on-year increase in net profit after deducting non-recurring gains and losses [1] Financial Performance - The company generated a net cash flow from operating activities of 1.211 billion yuan, representing a year-on-year increase of 54.98% [1] - The net profit after deducting non-recurring gains and losses reached 321 million yuan [1] Business Segments - The formulation sales business maintained steady growth, with products such as Saismei, Ximeixin, and Niuzaili showing sales revenue increases of over 30% [2] - Saismei, as the first domestically developed innovative drug in the cholesterol absorption inhibitor category, is highly recommended in national guidelines [2] - The company is focusing on chronic disease management, particularly in cardiovascular and metabolic diseases, and has initiated several health promotion projects [2] Product Development - Haizheng Pharmaceutical continues to deepen its presence in various disease areas, with Ximeixin leading in the market for cholestatic liver disease treatments and Niuzaili becoming a new standard for community-acquired infections [3] - The pet medicine sector showed strong growth, with overall sales increasing by over 60%, and the pet e-commerce business achieving sales exceeding 100 million yuan [3] - The company launched several new products in the pet healthcare market, including a new antibiotic for dogs and cats and a vaccine for cats [3] Strategic Initiatives - The establishment of a joint venture focused on synthetic biology marks a significant step into the high-end synthetic biology industry [4] - The company is enhancing internal operational efficiency through refined management of sales expenses and continuous technological innovation in production [4] - Looking ahead, Haizheng Pharmaceutical aims to leverage cutting-edge technologies such as synthetic biology and AI in drug development to enhance long-term value creation [4]